Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma

被引:41
作者
Calasanz, MJ
Cigudosa, JC
Odero, MD
GarciaFoncillas, J
Marin, J
Ardanaz, MT
Rocha, E
Gullon, A
机构
[1] UNIV NAVARRA,DEPT ONCOL,PAMPLONA 31008,SPAIN
[2] UNIV NAVARRA,DEPT HAEMATOL,PAMPLONA 31008,SPAIN
[3] HOSP NTRA S ARANZAZU,DEPT HAEMATOL,SAN SEBASTIAN,SPAIN
[4] HOSP TXAGORRITXU,DEPT HAEMATOL,VITORIA,SPAIN
关键词
multiple myeloma; survival analysis; hypodiploidy; 22q11; abnormalities; prognostic factors;
D O I
10.1046/j.1365-2141.1997.2443061.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our aim was to evaluate the clinical use of cytogenetic analysis as a prognostic factor in the outcome of newly diagnosed multiple myeloma (MM) patients, The present series includes 111 newly diagnosed MM patients treated with one of three standard-dose regimens or autologous transplantation over an 8-year time interval. As expected, the presence of an abnormal karyotype (39% of patients) correlated with poor prognosis (progression rate 63% v 47%, P=0.042), shorter event-free (EFS, P=0014) and overall (OS, P=0.005) survival, Two distinct cytogenetic abnormalities were the most significant variables that influenced EFS and OS in the univariate analysis, The presence of hypodiploid karyotypes or rearrangements of band 22q11 were associated with higher progression rate (P=0.001) and shorter EFS (P<0.024) and OS (P<0.004). The median EFS and OS for patients with hypodiploidy was 4 and 7 months respectively, Multivariate analysis showed that absence of hypodiploidy was the most favourable prognostic variable for OS (P=0.022) followed by stage less than or equal to IIA, serum calcium less than or equal to 2875 mu mol/l, and absence of abnormalities 22q. The data suggest that the presence of hypodiploid karyotypes and rearrangements on 2q11 band show a higher progression rate and shorter survival in MM patients.
引用
收藏
页码:418 / 425
页数:8
相关论文
共 31 条
  • [1] ALEXANIAN R, 1995, SEMIN HEMATOL, V32, P20
  • [2] BARLOGIE B, 1989, BLOOD, V73, P865
  • [3] BATAILLE R, 1992, BLOOD, V80, P733
  • [4] IMPACT OF RESPONSE TO TREATMENT ON SURVIVAL IN MULTIPLE-MYELOMA - RESULTS IN A SERIES OF 243 PATIENTS
    BLADE, J
    LOPEZGUILLERMO, A
    BOSCH, F
    CERVANTES, F
    REVERTER, JC
    MONTSERRAT, E
    ROZMAN, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (01) : 117 - 121
  • [5] Calasanz MJ, 1997, GENE CHROMOSOME CANC, V18, P84, DOI 10.1002/(SICI)1098-2264(199702)18:2<84::AID-GCC2>3.0.CO
  • [6] 2-X
  • [7] CYTOGENETIC DATA IN 41 PATIENTS WITH MULTIPLE-MYELOMA - KARYOTYPE AND OTHER CLINICAL-PARAMETERS
    CIGUDOSA, JC
    CALASANZ, MJ
    ODERO, MD
    PROSPER, F
    ETXANIZ, A
    MARIN, J
    RIFON, J
    GULLON, A
    ROCHA, E
    [J]. CANCER GENETICS AND CYTOGENETICS, 1994, 78 (02) : 210 - 213
  • [8] CORRADINI P, 1994, LEUKEMIA, V8, P758
  • [9] COX DR, 1972, J R STAT SOC B, V34, P187
  • [10] DEWALD GW, 1985, BLOOD, V66, P380